The Impact of Vitamin E Intake on Cardiometabolic Outcomes of Testosterone Replacement Therapy in Men with Late-Onset Hypogonadism
4 affiliations
- 1Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland
- 2Department of Pediatrics in Bytom, Faculty of Health Sciences in Katowice, Medical University of Silesia, Stefana Batorego 15, 41-902 Bytom, Poland
- 3Department of Pathophysiology, Faculty of Medicine, Academy of Silesia, Rolna 43, 40-555 Katowice, Poland
- 4Department of Molecular Biology, Medical University of Silesia, 40-752 Katowice, Poland
Abstract
Androgen deficiency is associated with an increased risk of cardiometabolic complications, whereas vitamin E may exert protective effects against cardiovascular and metabolic diseases. This pilot prospective cohort study examined whether cardiometabolic outcomes observed during exogenous testosterone therapy differed according to vitamin E intake in men with insufficient endogenous testosterone production. Three cohorts of men with late-onset hypogonadism (LOH) (n = 29 per group), matched for age, smoking status, body mass index, and baseline testosterone concentration, were classified according to vitamin E intake as low, adequate, or high; 29 men without LOH served as controls. Men with LOH received intramuscular testosterone injections every three weeks for six months. Cardiometabolic parameters were assessed before and after treatment, including biochemical markers, carotid intima–media thickness, retinal vascular sclerotic changes, and estimated 10-year cardiovascular risk. Compared with controls, men with LOH had higher HOMA-IR, LDL cholesterol, uric acid, fibrinogen, homocysteine, high-sensitivity C-reactive protein (hsCRP), urinary albumin-to-creatinine ratio (UACR), carotid intima–media thickness, and estimated 10-year cardiovascular risk. Elevations in homocysteine, hsCRP, and UACR were more pronounced in men with low or high vitamin E intake than in those with adequate intake. Testosterone levels increased during treatment in all groups. Improvements were observed in most cardiometabolic parameters in men with adequate vitamin E intake, whereas changes were limited to HOMA-IR in those with low intake. In men with high intake, no significant changes were observed except for a decrease in HDL cholesterol. At study completion, carotid intima–media thickness and retinal vascular sclerotic changes in men with adequate vitamin E intake did not differ significantly from those in controls. Changes in assessed risk factors correlated with increases in testosterone levels and mean daily vitamin E intake. These findings suggest an association between vitamin E intake and cardiometabolic outcomes observed during testosterone therapy in men with testosterone deficiency.
Related
- Diagnostic challenge of pulmonary embolism during testosterone replacement therapy for primary hypogonadism
- Testosterone Replacement Therapy and Associated Outcomes and Management of Trigger Finger.
- Fulminant Ischemic Colitis With Toxic Megacolon in a Young Man Receiving Testosterone Replacement Therapy Despite Therapeutic Phlebotomy for Hereditary Hemochromatosis: A Case Report
- Testosterone, Testosterone Replacement Therapy, and Cardiovascular Disease: A Contemporary Review
- Efficacy of Testosterone Replacement Therapy in Men WithHypogonadism: A Systematic Review and Meta-Analysis of ClinicalOutcomes, Body Composition, and Quality of Life
BibTeX
@article{krysiak2026impact,
title = {{The Impact of Vitamin E Intake on Cardiometabolic Outcomes of Testosterone Replacement Therapy in Men with Late-Onset Hypogonadism}},
author = {Robert Krysiak and Witold Szkróbka and Karolina Kowalcze and Grzegorz Machnik and Karolina Zapletal-Pudełko and Bogusław Okopień},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27208953},
url = {https://www.mdpi.com/1422-0067/27/20/8953},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The Impact of Vitamin E Intake on Cardiometabolic Outcomes of Testosterone Replacement Therapy in Men with Late-Onset Hypogonadism
AU - Robert Krysiak
AU - Witold Szkróbka
AU - Karolina Kowalcze
AU - Grzegorz Machnik
AU - Karolina Zapletal-Pudełko
AU - Bogusław Okopień
PY - 2026
DA - 2026/10/09
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27208953
UR - https://www.mdpi.com/1422-0067/27/20/8953
AB - Androgen deficiency is associated with an increased risk of cardiometabolic complications, whereas vitamin E may exert protective effects against cardiovascular and metabolic diseases. This pilot prospective cohort study examined whether cardiometabolic outcomes observed during exogenous testosterone therapy differed according to vitamin E intake in men with insufficient endogenous testosterone production. Three cohorts of men with late-onset hypogonadism (LOH) (n = 29 per group), matched for age, smoking status, body mass index, and baseline testosterone concentration, were classified according to vitamin E intake as low, adequate, or high; 29 men without LOH served as controls. Men with LOH received intramuscular testosterone injections every three weeks for six months. Cardiometabolic parameters were assessed before and after treatment, including biochemical markers, carotid intima–media thickness, retinal vascular sclerotic changes, and estimated 10-year cardiovascular risk. Compared with controls, men with LOH had higher HOMA-IR, LDL cholesterol, uric acid, fibrinogen, homocysteine, high-sensitivity C-reactive protein (hsCRP), urinary albumin-to-creatinine ratio (UACR), carotid intima–media thickness, and estimated 10-year cardiovascular risk. Elevations in homocysteine, hsCRP, and UACR were more pronounced in men with low or high vitamin E intake than in those with adequate intake. Testosterone levels increased during treatment in all groups. Improvements were observed in most cardiometabolic parameters in men with adequate vitamin E intake, whereas changes were limited to HOMA-IR in those with low intake. In men with high intake, no significant changes were observed except for a decrease in HDL cholesterol. At study completion, carotid intima–media thickness and retinal vascular sclerotic changes in men with adequate vitamin E intake did not differ significantly from those in controls. Changes in assessed risk factors correlated with increases in testosterone levels and mean daily vitamin E intake. These findings suggest an association between vitamin E intake and cardiometabolic outcomes observed during testosterone therapy in men with testosterone deficiency.
SN - 1422-0067
ER -